PMID- 14624904
OWN - NLM
STAT- MEDLINE
DCOM- 20031204
LR  - 20221207
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 62
IP  - 5
DP  - 2003 Nov
TI  - Complexed PSA performance for prostate cancer detection in an African-American 
      population.
PG  - 835-9
AB  - OBJECTIVES: Complexed prostate-specific antigen (cPSA) has been shown to improve 
      the differentiation of benign and malignant disease compared with total PSA 
      (tPSA) in studies evaluating predominantly white populations of men. We sought to 
      evaluate the diagnostic performance of cPSA relative to tPSA in a population of 
      African-American men. METHODS: Consecutive African-American men scheduled for 
      prostate biopsy were enrolled prospectively at the Louisiana State University 
      Medical Center, New Orleans. Serum was collected before the biopsy procedure and 
      tested with the Immuno 1 tPSA and cPSA methods. Receiver operating characteristic 
      curve analysis was performed and the area under the curve was calculated for tPSA 
      and cPSA. RESULTS: A total of 156 patients were evaluated, 51 (32.7%) of whom 
      were diagnosed with prostate cancer. The median PSA value for men with prostate 
      cancer was 4.96 ng/mL and for those with benign disease was 3.93 ng/mL. The 
      receiver operating characteristic analysis indicated that the area under the 
      curve for cPSA (0.679) was statistically greater than that achieved for tPSA 
      (0.642, P = 0.004). Using cutoff values for cPSA of 2.3 ng/mL and for tPSA of 
      2.85 ng/mL provided a specificity of 31.4% and 26.7%, respectively, at a 
      sensitivity for prostate cancer detection of 95%. This was not statistically 
      significant (P = 0.18). CONCLUSIONS: cPSA offers modest improvement in prostate 
      cancer detection compared with tPSA in African-American men, but not at the 
      clinically relevant 95% sensitivity level. Additional work is needed to improve 
      prostate cancer detection in this high-risk cohort of patients.
FAU - Martin, B
AU  - Martin B
AD  - Louisiana State University Medical Center, New Orleans, Louisiana 70112, USA.
FAU - Cheli, C D
AU  - Cheli CD
FAU - Lifsey, D
AU  - Lifsey D
FAU - Ward, M
AU  - Ward M
FAU - Pollard, S
AU  - Pollard S
FAU - Jefferson, L
AU  - Jefferson L
FAU - Thiel, R P
AU  - Thiel RP
FAU - Rayford, W
AU  - Rayford W
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Biomarkers, Tumor)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/*blood/diagnosis/ethnology/pathology
MH  - Adult
MH  - Black or African American
MH  - Aged
MH  - Area Under Curve
MH  - Biomarkers, Tumor/*blood
MH  - Biopsy, Needle
MH  - Humans
MH  - Louisiana/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/*blood/diagnosis/ethnology/pathology
MH  - ROC Curve
MH  - Sensitivity and Specificity
EDAT- 2003/11/20 05:00
MHDA- 2003/12/05 05:00
CRDT- 2003/11/20 05:00
PHST- 2003/11/20 05:00 [pubmed]
PHST- 2003/12/05 05:00 [medline]
PHST- 2003/11/20 05:00 [entrez]
AID - S0090429503006757 [pii]
AID - 10.1016/s0090-4295(03)00675-7 [doi]
PST - ppublish
SO  - Urology. 2003 Nov;62(5):835-9. doi: 10.1016/s0090-4295(03)00675-7.